CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. INFORMATION THAT WAS OMITTED HAS BEEN NOTED IN THIS DOCUMENT WITH A PLACEHOLDER IDENTIFIED BY THE MARK “[***]”.
LICENSE AND SUPPLY AGREEMENT
This License and Supply Agreement (“Agreement”) is made as of the 1st day of April 2023 (the “Effective Date”), by and between:
Coya Therapeutics Inc., a company registered under the laws of USA, and having its registered office at 5850 San Felipe St. Suite 500, Houston, Texas, USA, (hereinafter referred to as “Coya” which expression shall unless it be repugnant to the context or meaning thereof be deemed to mean and include its Affiliates, successors, and assigns);
and
Dr. Reddy’s Laboratories Ltd. a company registered under the laws of India, and having its place of business at 8-2-337, Road No. 3, Banjara Hills, Hyderabad, Telangana, India, (hereinafter referred to as “DRL” which expression shall unless it be repugnant to the context or meaning thereof be deemed to mean and include its Affiliates, successors, and assigns).
DRL and Coya may each be referred to individually as a “Party” and collectively as the “Parties.”
WHEREAS,
NOW, THEREFORE, in consideration of the foregoing and of the agreements, representations, covenants, and warranties contained herein, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows:
“Abatacept” means the fusion protein having the international nonproprietary name (INN) abatacept, comprising the extracellular domain of CTLA-4 with the hinge, CH2, and CH3 domains of IgG1.
“Affiliate” means a Person that controls, is controlled by or is under common control with a Party, but only for so long as such control exists. For the purposes of this definition of “Affiliate”, the word “control” (including, with correlative meaning, the terms “controlled by” or “under the common control with”) means the actual power, either directly or indirectly through one or more intermediaries, to direct the management and policies of such Person or entity, whether by the ownership of more than fifty percent (50%) of the voting stock of such entity, or by contract or otherwise.
“Agreement” has the meaning set forth in the initial paragraph of this Agreement.
“Applicable Laws” means all applicable laws, statutes, ordinances, codes, rules and regulations, including: (i) all applicable laws and regulations of the Territory, including those regarding cGMP and cGLP, (ii) all laws, ordinances, codes, rules and regulations as they apply to the Product and the Final Product, and (iii) those applicable to the development, manufacturing, import, offer to sell, sale, distribution, use, marketing or promotion of the Product and the Final Product or any aspect thereof and the obligations of Parties hereunder, as the context requires under this Agreement.
“Application” means the Dossier filing before the Regulatory Authority and any amendments or supplements thereto of the Final Product.
“Batch” means a specific quantity of a Product or Final Product that is intended to have uniform character and quality within specified limits and is produced according to a single manufacturing order during the same cycle of manufacture and designated by a batch number.
“Certificate of Analysis” means a document, which is dated and signed by a duly authorized representative of the quality control or quality assurance department of the manufacturer certifying that the Product meets the Product Specifications.
“Change in Control” means the occurrence of any of the following:
2
“Commercialization” means the marketing, promotion, distribution and sale of the Final Product(s) developed hereunder, any and all activities that relate to the marketing, promoting, distributing, importing or exporting for sale, offering for sale, and selling of such Final Product (including pre-launch and marketing preparation activities) and any interactions with Regulatory Authorities after receipt of Regulatory Approval regarding the foregoing.
“Commercially Reasonable Efforts” means with respect to the efforts to be expended by a Party regarding any objective under this Agreement, the reasonable, good-faith efforts to accomplish such objective that a reasonable Person similarly situated would normally use to accomplish a similar objective under similar circumstances exercising reasonable business judgment, taking into account, without limitation, (a) issues of safety, efficacy and product profile, (b) likelihood of receiving Regulatory Approval for the applicable product, (c) regulatory structure involved, and (d) actual or anticipated Regulatory Authority approved labeling. “Commercially Reasonable Efforts” will be determined on a country-by-country basis in the relevant countries, and activities that are conducted in one country that may contribute to achieving the relevant objective in another country will be considered in determining whether Commercially Reasonable Efforts have been applied in such other countries.
“Confidential Information” means all confidential or proprietary information relating to the Parties’ business and operation, this Agreement’s term sheet, this Agreement and its terms, or other technical, business or financial information provided by the Parties as contemplated by this Agreement. “Confidential Information” does not include information that (A) becomes generally available to the public other than as a result of disclosure by the receiving Party, (B) becomes available to the receiving Party on a non-confidential basis from a source other than the disclosing Party, provided that such source is not known by the receiving Party to be bound by a confidentiality agreement with the disclosing Party, (C) was previously known by the receiving Party as evidenced by the receiving Party’s written records, or (D) was independently developed by the receiving Party without use of or reliance on the Confidential Information.
“Control” or “Controlled” means with respect to a Party and to any IP and Know-How or materials, possession on the Effective Date or at any time during the Term of the ability by such Party or its Affiliate (whether by sole or joint ownership, license or otherwise), other than pursuant to this Agreement, to grant, without violating the terms of any agreement with a Third Party, a license, access or other right in, to or under such IP or Know-How or materials. Notwithstanding anything in this Agreement to the contrary, if a Party has undergone a Change in Control and is acquired by a Third Party or such Third Party’s Affiliates, then such Party will be deemed to not Control any IP and Know-How that is owned or controlled by such Third Party or such Third Party’s Affiliates, unless such IP and Know-How (a) was developed prior to the closing of such Change in Control, to the extent that any such IP and Know-How were discovered, developed, invented or created by such Third Party or such Third Party’s Affiliates prior to such Change in Control using or incorporating such Party’s or its pre-existing Affiliate’s IP and Know-How or (b) after the closing of such Change in Control to the extent
3
that such IP and Know-How (i) are discovered, developed, invented or created by such Third Party or such Third Party’s Affiliates (other than such Party or its pre-existing Affiliates) using or incorporating such Party’s or its pre-existing Affiliates’ IP and Know-How or any Confidential Information of either Party, or (ii) are discovered, developed, invented or created by personnel who were employees or consultants of such Party or its pre-existing Affiliates.
“Coya Licensed IP” means the IP and Know-How Controlled by Coya that is necessary or reasonably useful to exploit the Final Product in the DRL Territory.
“Coya Royalty Term” means on a country by country basis, the period beginning on the first commercial sale following receipt of Regulatory Approval of such Final Product in such country and expiring upon the Term of this Agreement.
“Coya Territory(ies)” means the exclusive territory of United States of America, Canada, European Union, United Kingdom, Japan, Mexico, South America where countries included in the European Union as of the Effective Date include the countries as outlined in the following link:
https://european-union.europa.eu/principles-countries-history/country-profiles_en
“DRL Licensed IP” means the IP and Know-How that DRL Controls on the Effective Date or during the Term that is necessary or reasonably useful to Develop, Commercialize, manufacture and otherwise exploit the Product and the Final Product in the Field. For clarity, the DRL Licensed IP shall include the Technical Package.
“DRL Royalty Term” means on a country by country basis, the period beginning on the first commercial sale following receipt of Regulatory Approval of such Final Product in such country and expiring upon the Term of this Agreement.
“DRL Territory(ies)” means all countries other than Coya Territory.
“Dossier” means the documentation prepared by Coya for the purpose of submission of the Application to obtain the Regulatory Approval of the Final Products in the Territory, prepared in e-CTD format.
“Effective Date” has the meaning set forth in the initial paragraph of this Agreement.
“FDA” means the United States Food and Drug Administration, or any successor agency.
“Final Product” means [***].
“Final Product Specifications” means the specifications as approved by the applicable Regulatory Authority, which may be amended from time to time as specifically requested by the applicable Regulatory Authority.
4
“Field” means [***].
“IFRS” means the International Financial Reporting Standards.
“IP and Know-How” means U.S. and non-U.S. (a) patents, utility models, supplementary protection certificates and applications thereof (including provisional applications, invention disclosures, certificates of invention and applications for certificates of invention) and divisional, continuations, continuations-in-part, reissues, renewals, extensions, re-examinations, and equivalents thereof, (b) trade secrets, know-how, proprietary information, inventions, discoveries, improvements, technology, technical data, work product and the contents thereof, and research and development, whether or not patentable, (c) trademarks, service marks, trade dress, trade names, and equivalents thereof, and (d) copyrights, mask works, registrations and applications thereof, and equivalents thereof.
“Licensee” means any Third Party licensed to Commercialize the Final Product in the Coya Territory pursuant to Section 2.3 or the DRL Territory pursuant to Section 2.4.
“Low Dose IL-2” means [***].
“Net Sales” means the aggregate gross amounts invoiced by a Party or its Affiliates or Licensees for the sales or other commercial distribution of the Final Product to each Third Party receiving the Final Product in arm’s length transactions, including to wholesalers and Third Party distributors, less the following deductions allowed or accrued by using IFRS:
(a) [***];
(b) [***];
(c) [***];
(d) [***]; and
(e) [***].
[***].
If a Party (sub)licenses the Final Product for its respective territory, then the Net Sales for the Final Product will be considered as per the aggregate gross amount invoiced by the Licensees less the above stated deductions allowed or accrued by using IFRS.
The foregoing deductions from the gross amount invoiced shall be deducted only once, and only to the extent not otherwise already deducted from the gross amount invoiced. All deductions provided above shall be based on accrual or actual basis.
Notwithstanding the foregoing, Net Sales shall not include amounts resulting from the sale or transfer of Final Product (i) to its Affiliates, or its or their permitted Licensees for subsequent
5
re-sale, (ii) sales for test marketing purposes or (iii) provided at or below cost as samples or for charitable purposes or compassionate use.
Net Sales shall be determined from the books and records of Parties and its Affiliates, as applicable, maintained in accordance with IFRS as regularly and consistently applied by Parties and its Affiliates, provided that such books and records are complete and accurate.
“Person” means any individual, partnership (general or limited), association, corporation, limited liability company, joint venture, trust, estate, limited liability partnership, unincorporated organization, government (or any agency or political subdivision thereof) or other legal person or organization.
“Product(s)” means [***].
“Product Specifications” means the specifications for the Product as agreed to by the Parties, which specifications may be amended from time to time by prior written agreement between the Parties.
“Purchase Order” has the meaning set forth in Section 5.2.
“Recall” has the meaning assigned in Section 8.1.
“Regulatory Approval” means the authorizations and approvals of any Regulatory Authority (including approvals of Applications) required for the Commercial manufacture, distribution, marketing, promotion, offer for sale, use, import, export or sale of Final Product(s) in the applicable country(ies) in the Territory, including, where required to Commercialize a Final Product, pricing and reimbursement approval.
“Regulatory Authority” means, with respect to a country in the Territory, any and all bodies and organizations (e.g., the FDA), regulating the manufacture, importation, marketing, distribution, use or sale of any of the Final Products in the Territory.
“Technical Package” shall mean the documentation with respect to the Product, which is under development by DRL, and which shall be proprietary to DRL, and such Technical Package shall include data to support the biosimilar registration submission of the Product with Regulatory Authorities in the United States of America.
“Term” has the meaning set forth in Section 13.1 of this Agreement.
“Territory” shall mean the Coya Territories and DRL Territories combined.
“Third Party” means any Person or entity other than a Party or any of its Affiliates.
6
7
8
Coya shall be responsible for the compilation of the Final Product Dossier for submission to Regulatory Authorities in the Coya Territory.
9
10
11
12
13
14
15
16
17
18
19
(i) for the prosecution and maintenance of patents as contemplated by this Agreement;
(ii) for submissions and other filings with Regulatory Authorities for the approval or other exploitation of a Product or Final Product as contemplated by this Agreement; or
(iii) to investors, bona fide potential investors, Licensees, bona fide potential business partners, lenders, acquirers, and investment bankers in connection with licensing, financing and acquisition activities, and due diligence processes related to such activities, provided that any such Third Party has entered into a written obligation to treat such information and materials as confidential and requiring at least commercially reasonable obligations of confidentiality (and each Party will remain responsible for any failure by any of the foregoing Persons, to whom a receiving Party may disclose Confidential Information) to treat such information as required under Section 15(b) hereof.
20
21
To: Coya
Coya Therapeutics, Inc.
5850 San Felipe St. Suite 500
Houston, TX 77057
Attention: CEO and CFO
admin@coyatherapeutics.com
To: DRL
Dr. Reddy’s Laboratories Ltd.
8-2-337, Road no.3, Banjara Hills,
Hyderabad-500034
Attention: General Counsel
22
23
IN WITNESS WHEREOF, the Parties have executed this Agreement on the date first above written.
Dr. Reddy’s Laboratories LTD.
By: /s/ Jayanth Sridhar
Name: Jayanth Sridhar
Title: Global Head of Biologics
COYA THERAPEUTICS, INC.
By: /s/ Howard Berman
Name: Howard Berman
Title: CEO
24
Annexure A
Milestones | Particulars | License Fee (in ‘000) |
One | [***] | [***] |
Two | [***] | [***] |
Three | [***] | [***] |
Four | [***] | [***] |
Five | [***] | [***] |
Six | [***] | [***] |
Seven | [***] | [***] |
Eight | [***] | [***] |
Nine | [***] | [***] |
Ten | [***] | [***] |
25
Annexure B
Net Sales value of the Final Product per annum | Royalty (as % of Net Sales value of Final Product |
< = [***] | [***] |
> [***] to [***] | [***] |
> [***] to [***] | [***] |
> [***] to [***] | [***] |
> [***] to [***] | [***] |
> [***] | [***] |
The higher royalty % will become applicable to the entire sales value if the Net Sales value crosses any of the defined threshold levels any time during the financial year.
Annexure C
Press Release
Coya Therapeutics, Inc. announces an Agreement with Dr. Reddy’s Laboratories, Ltd. to License its proposed biosimilar Abatacept for the Development, and Commercialization of COYA 302, Coya’s Proprietary Biologic Combination Product, for the Treatment of Neurodegenerative Diseases.
• COYA 302 is an investigational combination biologic for subcutaneous administration, comprised of COYA 301 and CTLA4-Ig (Abatacept). COYA 302 has a dual mechanism of action intended to suppress the chronic and sustained inflammation underlying certain neurodegenerative diseases.
• COYA 301 is an investigational immunomodulatory cytokine for subcutaneous administration intended to enhance regulatory T cell (Treg) function in vivo, and Abatacept is a fusion protein that binds to antigen-presenting cells and downregulates T effector cells and other pro-inflammatory cells.
• As part of the development of the combination product COYA 302, Coya will source CTLA4-Ig from Dr. Reddy’s.
26
• Under the terms of the agreement, Coya retains exclusive rights to develop and commercialize COYA 302 across multiple neurodegenerative diseases in multiple territories, including North and South America, the EU, United Kingdom, and Japan.
• Dr. Reddy’s obtains exclusive rights to commercialize COYA 302 across multiple neurodegenerative disease conditions in areas outside of Coya’s territory.
• Results from a proof-of-concept clinical study for COYA 302 evaluating pharmacodynamic, biomarker, safety, and preliminary efficacy parameters in patients with Amyotrophic Lateral Sclerosis (ALS) will be presented by Dr. Stanley Appel at the MDA Conference in Dallas, Texas on March 21, 2023.
Houston, TX, March XX, 2023 -- Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing multiple therapeutic platforms intended to enhance Treg function, including biologics and cell therapies, today announced a worldwide agreement with Dr. Reddy’s Laboratories Limited. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY; hereafter referred to as “Dr. Reddy’s”), a global pharmaceutical company. Under this agreement, Coya will in-license the proposed Abatacept biosimilar of Dr. Reddy’s for the development of Coya’s combination product for neurodegenerative diseases, COYA 302. It is a dual biologic intended to suppress neuroinflammation via multiple immunomodulatory pathways, for the treatment of neurodegenerative conditions.
COYA 302 is comprised of two components – COYA 301 and CTLA4-Ig. Coya will develop COYA 301. Under the terms of the Agreement, Coya has been granted an exclusive, royalty-bearing license to Dr. Reddy’s proposed biosimilar Abatacept for the development and commercialization of Coya 302 for the treatment of certain neurological diseases for sale in multiple territories including North and South America, the EU, United Kingdom, and Japan. As consideration for the license, Coya will pay a one-time non-refundable upfront fee to Dr. Reddy’s. In addition, Coya will owe tiered payments to Dr. Reddy’s based upon Coya’s achievement of certain developmental milestones. Coya will also owe royalties to Dr. Reddy’s on Net Sales of Coya 302 within its licensed territory on a tiered basis. The Agreement does not preclude Dr. Reddy’s from launching its proposed biosimilar Abatacept globally for approved indications post regulatory approval.
Coya anticipates that it will file an IND for COYA 302 in the 2H of 2023 with the goal of initiating a phase 1b/2 trial in ALS (Amyotrophic Lateral Sclerosis) soon thereafter.
The Agreement also provides for the license of Coya 301, Coya’s low dose IL-2 to Dr. Reddy’s to permit the commercialization by Dr. Reddy’s of Coya 302 in territories not otherwise granted to Coya. Coya will receive royalties on Net Sales by Dr. Reddy’s in their territories based on the same tiered structure as Coya owes Dr. Reddy’s. The Agreement also allows Dr. Reddy’s and Coya to enter into a mutually satisfactory commercial supply agreement at an appropriate time.
“This is a landmark agreement for Coya in our efforts to develop COYA 302. To partner with such a high-caliber pharmaceutical company like Dr. Reddy’s is what every emerging biotechnology company strives for, and we believe that the combined resources of both organizations strengthen our chances to bring this therapeutic modality to patients with neurodegenerative diseases if approved by regulatory authorities,” commented Howard H Berman, Ph.D., CEO of Coya Therapeutics.
Adrian Hepner, M.D., Ph.D. and CMO of Coya added, “we believe that the COYA 302 proof-of-concept clinical data in ALS patients is encouraging and sets the foundation to advance our development program. Our combination therapy approach has been designed to address the multiple pathophysiological pathways leading to chronic and sustained inflammation that drives the progression of serious neurodegenerative
27
diseases. We plan to file an IND in the second half of this year and work closely with the regulatory authorities to initiate our clinical studies soon thereafter.”
Jayanth Sridhar, Global Head of Biologics at Dr. Reddy’s commented, “We are very happy to collaborate with Coya in this effort to advance therapies that address critical unmet needs for a variety of neuro-degenerative diseases. As a global biosimilars developer, we believe our proposed Abatacept biosimilar will be valuable in the development of this innovative combination therapy. We continue to look for ways to use our scientific capabilities and product portfolio to serve patients around the world.”
About Coya Therapeutics, Inc.
Headquartered in Houston, TX, Coya Therapeutics, Inc. (Nasdaq: COYA) is a clinical-stage biotechnology company developing proprietary treatments focused on the biology and potential therapeutic advantages of regulatory T cells (“Tregs”) to target systemic inflammation and neuroinflammation. Dysfunctional Tregs underlie numerous conditions including neurodegenerative, metabolic, and autoimmune diseases, and this cellular dysfunction may lead to a sustained inflammation and oxidative stress resulting in lack of homeostasis of the immune system. Coya’s investigational product candidate pipeline leverages multiple therapeutic modalities aimed at restoring the anti-inflammatory and immunomodulatory functions of Tregs. Coya’s therapeutic platforms include Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. Coya’s 300 Series product candidates, COYA 301 and COYA 302, are biologic therapies intended to enhance Treg function and expand Treg numbers. COYA 301 is a cytokine biologic for subcutaneous administration intended to enhance Treg function and expand Treg numbers in vivo, and COYA 302 is a biologic combination for subcutaneous and/or intravenous administration intended to enhance Treg function while depleting T effector function and activated macrophages. These two mechanisms may be additive or synergistic in suppressing inflammation.
For more information about Coya, please visit www.coyatherapeutics.com
About Dr. Reddy’s Laboratories
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is a global pharmaceutical company headquartered in Hyderabad, India. Established in 1984, we are committed to providing access to affordable and innovative medicines. Driven by our purpose of ‘Good Health Can’t Wait’, we offer a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Our major markets include – USA, India, Russia & CIS countries, China, Brazil and Europe. As a company with a history of deep science that has led to several industry firsts, we continue to plan ahead and invest in businesses of the future. As an early adopter of sustainability and ESG actions, we released our first Sustainability Report in 2004. Our current ESG goals aim to set the bar high in environmental stewardship; access and affordability for patients; diversity; and governance. For more information, log on to: www.drreddys.com.
Forward-Looking Statements
This press release contains “forward-looking” statements that are based on our management’s beliefs and assumptions and on information currently available to management. Forward-looking statements include all statements other than statements of historical fact contained in this presentation, including information concerning our current and future financial performance, business plans and objectives, current and future clinical and preclinical development activities, timing and success of our ongoing and planned clinical trials and related data, the timing of announcements, updates and results of our clinical trials and related data, our ability to obtain and maintain regulatory approval, the potential therapeutic benefits and economic value of our product candidates, competitive position, industry environment and potential market opportunities. The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” and similar expressions are intended to identify forward-looking statements.
28
Forward-looking statements are subject to known and unknown risks, uncertainties, assumptions and other factors including, but not limited to, those related to risks associated with the impact of COVID-19; the success, cost and timing of our product candidate development activities and ongoing and planned clinical trials; our plans to develop and commercialize targeted therapeutics; the progress of patient enrollment and dosing in our preclinical or clinical trials; the ability of our product candidates to achieve applicable endpoints in the clinical trials; the safety profile of our product candidates; the potential for data from our clinical trials to support a marketing application, as well as the timing of these events; our ability to obtain funding for our operations; development and commercialization of our product candidates; the timing of and our ability to obtain and maintain regulatory approvals; the rate and degree of market acceptance and clinical utility of our product candidates; the size and growth potential of the markets for our product candidates, and our ability to serve those markets; our commercialization, marketing and manufacturing capabilities and strategy; future agreements with third parties in connection with the commercialization of our product candidates; our expectations regarding our ability to obtain and maintain intellectual property protection; our dependence on third party manufacturers; the success of competing therapies or products that are or may become available; our ability to attract and retain key scientific or management personnel; our ability to identify additional product candidates with significant commercial potential consistent with our commercial objectives; ; and our estimates regarding expenses, future revenue, capital requirements and needs for additional financing.
We have based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, business strategy, short-term and long-term business operations and objectives, and financial needs. Moreover, we operate in a very competitive and rapidly changing environment, and new risks may emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed herein may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Although our management believes that the expectations reflected in our forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances described in the forward-looking statements will be achieved or occur. We undertake no obligation to publicly update any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
Investor Contact
David Snyder
david@coyatherapeutics.com
Hayden IR
James Carbonara
(646)-755-7412
James@haydenir.com
Media Contact
Jessica Starman
media@coyatherapeutics.com
29
Annexure - D
It is the policy of DRL and its subsidiaries, affiliates, to ensure full compliance with all anti-bribery and anti-corruption laws and regulations applicable in the respective jurisdiction where it conducts business. Therefore, DRL requires all of its business partners to conduct their DRL’s related work in accordance with these principles.
Accordingly, as a business partner of DRL, pursuant to this Agreement between DRL and Coya, the undersigned, hereby certifies for and on behalf of Coya that:
I declare that I have examined this Certificate on 16-Mar-2023 | 11:44 PM IST and to the best of my knowledge, belief it is true, correct and complete. I further declare that I have the authority to sign this document on behalf of Coya.
By: /s/ Howard Berman
Name: Howard Berman
Title: CEO
30